William G. Kaelin Jr., MD | Nobel Prize Press Conference, October 7, 2019

Scientists won the Nobel Prize
12 followers
So this revolutionary moment actually reminds me of a musical verse from the Hollies that goes,
sometimes all I need is the air I breathe. And of course, it's the oxygen in that air
that we need the most. Today's Nobel Prize winners, including Dana Farber's own Bill Kalin,
have been deservedly launched, lauded for discovering the pathways by which cells,
especially human cells, including cancer cells, sense and adapt to changes in the availability
of oxygen. Oxygen is essential for survival, as we all know, and understanding it and being able
to manipulate it are already being used by Bill and others to develop exciting new treatments
for cancer, for cardiovascular disease, for anemia, and for macular degeneration.
Oxygen is truly an amazing substance. It fuels fires, it corrodes metals,
and even though we need it to survive, too much can actually be toxic. I mean, think about this.
If you climb above about 26,000 feet, you enter what's called the death zone,
and it gets its name because you don't have enough oxygen to survive at that altitude.
The need for oxygen is something every mountain climber is familiar with, yet most people
take it for granted. But every animal and human cell knows that it's so important that it has
a special machinery to sense the availability of oxygen and adjust the metabolism and growth
properties of that cell. Dana Farber's Bill Kalin and two other scientists, as you know,
were awarded the Nobel Prize today for discovering that sensing mechanism. It's
a discovery that has already led to important medical applications in areas like cancer,
where the availability of oxygen is critical to the way cancer cells grow and survive.
We're truly in a revolutionary time for cancer care, and what Dr. Kalin and his collaborators
discovered is absolutely transformative. This is all about the importance of understanding
the basic biology of the human body, and it's only from that understanding that we can best
attack cancer. So this marriage of basic science, clinical research, and patient care is what is so
powerful about what we do here at Dana Farber. We're all incredibly proud of Dr. Kalin and
hopeful for the promise that this means for patients here and everywhere. Thank you.
Bill, and I forgot to actually put this in, but you should know that Bill is the Sidney
Farber Professor of Medicine at Dana Farber Cancer Institute and at Harvard Medical School,
Professor of Medicine at Harvard Medical School, and at Brigham and Women's Hospital.
And it's lovely to have the Dean of Harvard Medical School, George Daly, and the President
of Brigham and Women's Hospital, Dr. Betsy Nabel, here to also say a few words. Thanks.
Well, as the Dean of Harvard Medical School, as a fellow scientist, and as a hematologist,
I could not be more proud of the scientific achievements that we're celebrating today.
This discovery of how oxygen interacts with tissues is a powerful reminder for how important
critical discoveries and how the most transformative therapies flow from the
deepest understanding of basic mechanisms. They also underscore the power of clinical observations
to inform basic discovery. I've known Bill for a number of years now, and he is the consummate
physician scientist. He's fiercely dedicated to rigor and excellence in both the laboratory
and in the clinic. Bill Kalin is the finest that medicine has to offer, and it is a privilege to
be here to offer my congratulations to Bill, to Peter, and Greg. Thank you.
Good morning. I'm Betsy Nabel, President of Brigham and Women's Hospital, and on behalf of
Brigham and Women's Hospital, I want to offer our congratulations to you, Bill, and to your family
as well for your extraordinary accomplishments and achievements. I can say that as a proudful
part of the Dana-Farber Brigham and Women's Cancer Center, we have great pride in the scientific
research discovery innovation that occurs here at the Dana-Farber Cancer Institute,
and that pride extends to taking those basic discoveries and translating them to new advances
for patients to improve their lives on a daily basis. So, Bill, we're so proud of your extraordinary
accomplishments. As an aside, I'm a cardiovascular scientist, so you might say, well,
what do the cardiovascular sciences have to do with oxygen and oxygen sensing? Well, actually,
a lot. The discoveries made by Bill and his colleagues have fundamentally defined how cells
in the body sense oxygen and then how the cells then response to either an abundance of oxygen
or an absence of oxygen, and you can imagine that in heart and blood vessels, as in a heart attack,
there's often an absence of oxygen, and so this oxygen sensing mechanism is critical for regulating
blood vessel tone and is critical in the development of a heart attack and the treatment to a heart
attack. So, Bill's work has had broad application across many fields of medicine, heart and
vascular disease, pulmonary disease, lung disease, kidney disease, and many other organ systems that
we care for individuals who have those diseases day in and day out at Brigham and Women's Hospital.
So, Bill's advances are cancer and way beyond, and for that, Bill, we're enormously grateful,
and I think, Bill, we also, just on a very personal note, not only are you a consummate
physician scientist, but you are a wonderful, amazing individual and human being, and we can't
think of a more glorious thing happening to such a wonderful individual, and for that, we're very
grateful and proud as well. Pleasure of introducing the star of the year, Bill Kalin.
Thank you very much, and thank you for those very kind words, and thank you for being here.
I hope you're all having a nice day, but I'm going to go out on a limb and say,
it's not as nice as the day I'm having. And on the way over here, I was teasing Lori
Glimcher because we just rolled out our new insignia this week for the Day of Barber,
and I said, way to do a new rollout. This really will help with the branding.
You know, I will confess, like most scientists and maybe all scientists, that they're being
honest. I did occasionally allow myself to dream that maybe one day this would happen.
Now, I don't think that's necessarily the health-based thing to do, so I try to ignore
that most days and try to completely not think about this and to try to think about my work.
When I was younger, my late wife and I would have fun together and talk about what would happen,
what would it be like if you ever won this prize. I say that because I'm accepting this prize
partly on behalf of my late wife, who herself was a faculty member at the Dana-Farber Cancer
Institute and the Brigham and Women's Hospital. She was a pioneering breast surgeon, and she was
my best friend and hero and partner in everything I did. To be honest, there were a couple of years
after I lost her that I thought, please, not a prize, because it would just be too bittersweet
and it would be too crushing to receive such a wonderful recognition without Carolyn. But I'm
at a point now where I like to think she's smiling down and nodding and saying, yeah, I told you,
I told you this was going to happen. And I'm thrilled to share this with my son, Trip, who's
here, and my daughter, who is currently a graduate student at Oxford, so we've already FaceTimed
this morning. And so I accept this partly on behalf of my family and my many friends who have
supported me. You know, I also learned years ago that I've grown the fastest when I've been
surrounded by people who were smarter than me and more knowledgeable than me and had better judgment
than me. And so one of the best decisions I ever made was to come to the Dana-Farber for my early
training. And more importantly, when I had the opportunity to leave, my choice was to stay,
because I wanted to be in a place where the people and the environment were going to make my
work better. You know, science, especially today, is not done by an individual. It's done by
an ecosystem. And I've been aided countless times by generous collaborators, the endless
stream of incredibly talented young people who have worked in my laboratory over the years,
without whom these discoveries would not have been possible. I also want to highlight David
Livingston, who's a professor here at the Dana-Farber Cancer Institute. He's my mentor.
Now, you'll notice I didn't say he was my mentor. He is my mentor. He taught me how to be a scientist
in the 80s and 90s. But he's, to this day, one of the people I go to when I need
sage advice. So there have been countless examples where my work has been made
better and made possible by the constant interactions, not only within the Dana-Farber
and the Brigham and Women's Hospital and Harvard Medical School, but this incredible biomedical
ecosystem that's now developed in Boston. So I think there was a time when you were an athlete,
you wanted to be in Sparta. But I think if you want to do biomedical research, there aren't too
many places that are any better than Boston. And again, I'm just so thrilled to be able to share
this prize with the many, many people who have helped me over the years and have made this
recognition possible. So thank you. We can take a few questions, if we have any questions.
You began this work with an investigation of von Hippel-Lindau disease. Could you tell us a
little bit about that disease and how that led to the broader work that you're doing for the
board today? Yes. So von Hippel-Lindau disease is a hereditary cancer syndrome that was first
described about 100 years ago. But we can now say in hindsight, there were people with von
Hippel-Lindau disease living in the Middle Ages. And these patients inherit a defective or altered
version of what we now call the DHL gene from either their mother or their father. And they
predictably over time, often in early adulthood, develop a variety of tumors. And these tumors
that they develop have some unusual features, including the fact that they are notorious for
overproducing the distress signals, if you will, that would normally be sent by a tissue if it
wasn't getting enough oxygen. So this was a clue that maybe the DHL gene, and I should point out,
you're probably aware, the DHL gene, like most genes, is a blueprint for making a protein. So
it's really the DHL protein that's doing the work. This was a clue that when you didn't have the DHL
gene or you didn't have the DHL protein, somehow oxygen sensing went awry, that these cells could
no longer tell whether they were getting enough oxygen or not. And in particular, were behaving
as though they weren't getting enough oxygen and were overproducing various distress signals that
are linked to, for example, red blood cell production, formation of new blood vessels,
metabolism, et cetera. And in the introductory remarks, I think it was alluded to the fact that
all three of the recipients this year are actually physician scientists. And so even
though all three of us were trained to do basic mechanistic work, and one of my take-home messages
here is there are no shortcuts. I think you have to do the basic mechanistic work, and it's only
through that basic mechanistic work that you can accumulate enough knowledge that you can actually
finally do something. But the reason I point this out is when I was much younger, I thought I was
going to be a clinician and not a scientist, and I was actually a chief medical resident at Johns
Hopkins Hospital. And chief residents are notorious for terrorizing their trainees with their knowledge
of obscure diseases that no one has ever heard about. And so that's one of the reasons I knew
about von Hippel-Lindau disease. But again, I thought this would be sort of a Rosetta Stone for studying
oxygen sensing. And by the way, in the early 90s, for example, there was a lot of excitement about
treating cancers with so-called angiogenesis inhibitors, such as endostatin and angiostatin,
based in part on the pioneering work of Judah Folkman. But I thought the idea was right,
let's try to block angiogenesis. But we didn't even know the mechanisms of action at the time for
angiostatin and endostatin. So it seemed to me we had to understand the molecular circuits that
cells use to respond to oxygen and the molecular circuits that, for example, control
angiogenesis. And then maybe we could make more targeted drugs that would be mechanism
based. It's a very long answer. I'm sorry, but that's how we got into that. Yes?
I have two questions for you. Can you just talk about the phone call this morning,
when it came and what you said? Yes. So I mentioned, and again,
I think any scientist who says he's never or she's never considered this moment is probably lying.
I do a pretty good job ignoring the Nobel Prize most of the year because I want to stay focused
on what I do. But of course, this time of year, it gets a little bit harder. So I was aware this
Nobel Prize Monday. But I think I was very good. I went to sleep at the appropriate time. And my
view has always been if it happens one day, it happens one day. And if it doesn't, it doesn't
really go back to my work. And I had a very vivid dream where I looked at the alarm clock,
and it said 545. So in my dream, I said, OK, another year. It didn't happen. But again,
you're OK, and you'll go back to work, and life will move on. I then woke up, and I saw the clock
was 2.30. It wasn't 5.30. And I think, oh, my god, I've got to go back to sleep and just got to do
this drill one more time. So then when the phone rang at 10 minutes to 5, now I'm like, is this
the dream part or is this the awake part? And I answered the phone. Of course, I cheated a little
bit because I could see it was a phone call caller ID that had many, many, many digits. So I knew it
wasn't coming from Saugus. So at that point, I think it was just so surreal. And I had this
out-of-body feeling of just great appreciation. And again, I'm just so thrilled to share this
with all the people who have meant so much to me in my life.
And Carolyn, I'm Channel 5. Can you just talk a little bit about how she inspires you now and
maybe what your hopes are for the future with cancer patients relating to the research you've
done and the work you've been doing? Yeah, well, great question. Well, anybody who knew Carolyn and
in particular the people she cared for would have told you that she was just the most amazing
physician they had ever met. And it wasn't that uncommon that she would be found holding the
hands of her patients. And sometimes while they were in tears, she would be in tears as well. So
Carolyn was about excellence and integrity and compassion in everything she did. So I try to hold
myself to those very high standards to try to conduct my work in the proper way. I also think
both through her career but also just walking through the waiting areas at the Dana-Farber,
you are reminded daily that there are people counting on us. And it's not about, frankly,
the awards and accolades, although they're wonderful when they come. But it's about trying
to get to the truth and to generate new knowledge and to have that knowledge eventually hopefully
help our patients. So I think both Carolyn and working at a place that actually sees patients
has been very grounding for me. Tell us a little bit about life in your lab. Do you arrive early
every day? Do you have particular habits that... Well, so for example, Carolyn was a surgeon and
I think even in medical school, I crossed off surgery as a career path because I didn't like
waking up at 5.30 in the morning. So I'm always been sort of a night person who likes to sleep
in a little bit and then arrive late. And so that's my style. And frankly, as I mentioned,
one of the many wonderful things about being at the Dana-Farber is we just attract such
tremendously talented young people. And if you want to know where great science is happening,
just look for the places that have a line out the door of young scientists waiting to train there.
And so my first job is not to mess it up. I try to create an environment where they can succeed
and then over time try to understand what styles work best for me in terms of mentoring because
it's not one size fits all. So I think like most successful lab directors, I try to create an
environment where people can succeed, set a tone. And I think the other thing that I would say,
since I'm often asked about working on Von Hippel-Lindau disease, I've sometimes used the
metaphor that when I was young, my father's favorite activity was to go fishing. And we
all know you could send 10 fishermen in different directions and then the first approximation they
know how to fish. But part of the secret is knowing where to fish. And there's a lot of
guesswork involved. And that's why any scientist, again, if they're lucky, if they're honest,
would admit there's some luck involved in this. But one thing I got right was I think
understanding that the Von Hippel-Lindau disease was a good place to go fishing.
So part of my job as a lab director is to try to understand what areas might be the next VHL
disease that we might want to work on that might be fertile for exploration.
How many people are in your lab?
At any given time, there are about 15 people, most of whom are postdoctoral fellows. We have
a few technicians as well. I'm personally a believer that labs can be too big or too small.
So I sort of like that 10 to 15.
Is there a sense of community there?
Well, some of them are standing in the back of the room. So I'm waiting to see what kind
of body language they're going to project here. But yes, I think there's a, you know,
when I'm picking people to work in my lab, you know, one of the criteria that's at or near the
top is for want of a better term, is this a nice person? And do I think they're honest?
Because if those two things are wrong, I don't care how smart they are. I don't care how
technically gifted they are. Because we're all in this together. We benefit tremendously from
collaborations within our laboratory, but also collaborations with other laboratories. And so
it's really critical that we create an environment where people
can work together and enjoy working together and where each can support one another.
Congratulations. I'm Christy Lee with NBC 10 Boston, the health reporter.
Can you tell me about how this discovery is already being applied, as has been said,
and also what other diseases and cancers you can apply it?
Yes. So, you know, usually you can use the metaphor at a high altitude view,
but inoxidant sensing, that sometimes leads to other thoughts. But, you know,
broadly what my co-awardees and I identified was a molecular pathway that allows cells to
sense oxygen. And depending on how much oxygen they're getting to respond appropriately by
turning on specific genes that, for example, might stimulate red blood cell production or
might stimulate blood vessel formation. So there are many diseases characterized by inadequate
oxygen delivery, one of which is anemia, but also certain cardiovascular diseases.
And so now for the first time we have pharmacological tools that can activate this
pathway and can trick the body into, for example, thinking you've gone to the top of
Everest. So there's an orally available, there's a series of orally available drugs
that are being tested now where the patient will take the drug, the body thinks it's at
high altitude and starts making more red blood cells. And there are literally millions of people
around the globe who walk around with low red blood cell counts, anemia being inadequate
red blood cells. And in certain parts of the world transfusing those patients or giving them
an expensive hormone such as erythropoietin is not really a viable option. So perhaps for that
reason the first approval of the first of these drugs took place in China in 2018. Japan just
approved it about a month or so ago and the filing for U.S. approval will take place later this month.
